nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ABCC8—forebrain—attention deficit hyperactivity disorder	0.0306	0.104	CbGeAlD
Gliclazide—KCNJ11—cardiovascular system—attention deficit hyperactivity disorder	0.0281	0.095	CbGeAlD
Gliclazide—ABCC8—Regulation of insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.0265	0.0376	CbGpPWpGaD
Gliclazide—ABCC8—cardiovascular system—attention deficit hyperactivity disorder	0.0259	0.0875	CbGeAlD
Gliclazide—KCNJ11—Regulation of insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.0257	0.0365	CbGpPWpGaD
Gliclazide—VEGFA—Regulation of gene expression by Hypoxia-inducible Factor—EP300—attention deficit hyperactivity disorder	0.0242	0.0344	CbGpPWpGaD
Gliclazide—VEGFA—cerebellum—attention deficit hyperactivity disorder	0.0237	0.0803	CbGeAlD
Gliclazide—ABCC8—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.0208	0.0296	CbGpPWpGaD
Gliclazide—ABCC8—midbrain—attention deficit hyperactivity disorder	0.0202	0.0684	CbGeAlD
Gliclazide—KCNJ11—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.0202	0.0287	CbGpPWpGaD
Gliclazide—VEGFA—brain—attention deficit hyperactivity disorder	0.0193	0.0652	CbGeAlD
Gliclazide—ABCC8—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.0183	0.026	CbGpPWpGaD
Gliclazide—KCNJ11—nervous system—attention deficit hyperactivity disorder	0.0181	0.061	CbGeAlD
Gliclazide—KCNJ11—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.0177	0.0252	CbGpPWpGaD
Gliclazide—KCNJ11—central nervous system—attention deficit hyperactivity disorder	0.0174	0.0587	CbGeAlD
Gliclazide—KCNJ11—cerebellum—attention deficit hyperactivity disorder	0.017	0.0574	CbGeAlD
Gliclazide—ABCC8—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.0167	0.0238	CbGpPWpGaD
Gliclazide—ABCC8—nervous system—attention deficit hyperactivity disorder	0.0166	0.0562	CbGeAlD
Gliclazide—KCNJ11—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.0162	0.023	CbGpPWpGaD
Gliclazide—ABCC8—central nervous system—attention deficit hyperactivity disorder	0.016	0.0541	CbGeAlD
Gliclazide—ABCC8—cerebellum—attention deficit hyperactivity disorder	0.0156	0.0529	CbGeAlD
Gliclazide—ABCC8—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.0146	0.0208	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.0144	0.0204	CbGpPWpGaD
Gliclazide—KCNJ11—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.0142	0.0201	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.014	0.0198	CbGpPWpGaD
Gliclazide—ABCC8—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.0139	0.0198	CbGpPWpGaD
Gliclazide—KCNJ11—brain—attention deficit hyperactivity disorder	0.0138	0.0466	CbGeAlD
Gliclazide—KCNJ11—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.0135	0.0192	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.0132	0.0187	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.0128	0.0181	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.0128	0.0181	CbGpPWpGaD
Gliclazide—ABCC8—brain—attention deficit hyperactivity disorder	0.0127	0.043	CbGeAlD
Gliclazide—KCNJ11—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.0124	0.0176	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—BDNF—attention deficit hyperactivity disorder	0.0122	0.0173	CbGpPWpGaD
Gliclazide—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.0116	0.0391	CbGeAlD
Gliclazide—ABCC8—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.0115	0.0163	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.0112	0.0158	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.0109	0.0155	CbGpPWpGaD
Gliclazide—VEGFA—Cellular response to hypoxia—EP300—attention deficit hyperactivity disorder	0.0107	0.0152	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.0106	0.0151	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.0104	0.0148	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.0095	0.0135	CbGpPWpGaD
Gliclazide—ALB—brain—attention deficit hyperactivity disorder	0.0091	0.0308	CbGeAlD
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00835	0.0119	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00817	0.0116	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.0076	0.0108	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.0076	0.0108	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—ANK3—attention deficit hyperactivity disorder	0.00752	0.0107	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00719	0.0102	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00696	0.00988	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00686	0.00974	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00656	0.00931	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00653	0.00928	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00633	0.009	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00572	0.00812	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00562	0.00798	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00552	0.00783	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00547	0.00777	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00545	0.00774	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00537	0.00763	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00536	0.00762	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.0053	0.00752	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00522	0.00742	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00506	0.00719	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00491	0.00698	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.00484	0.00688	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00469	0.00666	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00466	0.00662	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00465	0.00661	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00456	0.00648	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00451	0.00641	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00396	0.00562	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00393	0.00558	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00384	0.00545	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00381	0.00541	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00378	0.00537	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00368	0.00522	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00346	0.00491	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00315	0.00448	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00288	0.00408	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00282	0.00401	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00271	0.00386	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00253	0.0036	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.0025	0.00355	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00247	0.00351	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00238	0.00338	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00232	0.00329	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00231	0.00328	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00221	0.00314	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00212	0.00301	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.0021	0.00298	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00193	0.00274	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.0019	0.00269	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00182	0.00259	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00178	0.00253	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00175	0.00248	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00169	0.0024	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00167	0.00238	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00166	0.00236	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00165	0.00234	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00165	0.00234	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.00162	0.0023	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00162	0.0023	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TPH2—attention deficit hyperactivity disorder	0.0016	0.00227	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.0016	0.00227	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00159	0.00226	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00157	0.00223	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00154	0.00218	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00153	0.00217	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00152	0.00215	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.0015	0.00214	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00146	0.00207	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00132	0.00187	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00128	0.00181	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00125	0.00178	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00124	0.00176	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00121	0.00172	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00108	0.00153	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.001	0.00143	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000997	0.00142	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000996	0.00141	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00099	0.00141	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000982	0.00139	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000973	0.00138	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—COMT—attention deficit hyperactivity disorder	0.000966	0.00137	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000963	0.00137	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00096	0.00136	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000956	0.00136	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000945	0.00134	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00088	0.00125	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000807	0.00115	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000768	0.00109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00069	0.00098	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000629	0.000893	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000616	0.000875	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00053	0.000753	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00053	0.000753	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000522	0.000741	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000485	0.000689	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000476	0.000676	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000476	0.000676	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000468	0.000665	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000435	0.000618	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000434	0.000617	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000434	0.000617	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—attention deficit hyperactivity disorder	0.000427	0.000607	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000427	0.000607	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000424	0.000602	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—attention deficit hyperactivity disorder	0.000414	0.000589	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000404	0.000573	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000397	0.000564	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000381	0.000541	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000362	0.000515	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000347	0.000493	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—attention deficit hyperactivity disorder	0.00034	0.000483	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00033	0.000469	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000327	0.000464	CbGpPWpGaD
Gliclazide—ALB—Metabolism—COMT—attention deficit hyperactivity disorder	0.000321	0.000456	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000319	0.000453	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000309	0.000439	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	0.000288	0.00041	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000286	0.000407	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000278	0.000394	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000263	0.000374	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000261	0.000371	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000253	0.00036	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—attention deficit hyperactivity disorder	0.000138	0.000196	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	0.000124	0.000176	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	0.000113	0.00016	CbGpPWpGaD
